Zhou, Q.* ; Mareljic, N.* ; Michaelsen, M.* ; Parhizkar, S.* ; Heindl, S.* ; Nuscher, B.* ; Farny, D.* ; Czuppa, M.* ; Schludi, C.* ; Graf, A.* ; Krebs, S.* ; Blum, H.* ; Feederle, R. ; Roth, S.* ; Haass, C.* ; Arzberger, T.* ; Liesz, A.* ; Edbauer, D.*
Active poly-GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model.
EMBO Mol. Med. 12:e10919 (2020)
The C9orf72 repeat expansion is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD). Non-canonical translation of the expanded repeat results in abundant poly-GA inclusion pathology throughout the CNS. (GA)(149)-CFP expression in mice triggers motor deficits and neuroinflammation. Since poly-GA is transmitted between cells, we investigated the therapeutic potential of anti-GA antibodies by vaccinating (GA)(149)-CFP mice. To overcome poor immunogenicity, we compared the antibody response of multivalent ovalbumin-(GA)(10) conjugates and pre-aggregated carrier-free (GA)(15). Only ovalbumin-(GA)(10) immunization induced a strong anti-GA response. The resulting antisera detected poly-GA aggregates in cell culture and patient tissue. Ovalbumin-(GA)(10) immunization largely rescued the motor function in (GA)(149)-CFP transgenic mice and reduced poly-GA inclusions. Transcriptome analysis showed less neuroinflammation in ovalbumin-(GA)(10)-immunized poly-GA mice, which was corroborated by semiquantitative and morphological analysis of microglia/macrophages. Moreover, cytoplasmic TDP-43 mislocalization and levels of the neurofilament light chain in the CSF were reduced, suggesting neuroaxonal damage is reduced. Our data suggest that immunotherapy may be a viable primary prevention strategy for ALS/FTD in C9orf72 mutation carriers.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Amyotrophic Lateral Sclerosis ; C9orf72 ; Frontotemporal Dementia ; Immunotherapy ; Neurodegeneration; Dipeptide-repeat Proteins; To-cell Transmission; Alpha-synuclein; Hexanucleotide Repeat; Cerebrospinal-fluid; Alzheimers-disease; Kappa-b; Tau; Pathology; Immunotherapy
Keywords plus
Language
english
Publication Year
2020
Prepublished in Year
2019
HGF-reported in Year
2019
ISSN (print) / ISBN
1757-4676
e-ISSN
1757-4684
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 12,
Issue: 2,
Pages: ,
Article Number: e10919
Supplement: ,
Series
Publisher
Wiley
Publishing Place
Chichester
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
Institute(s)
CF Monoclonal Antibodies (CF-MAB)
POF-Topic(s)
30201 - Metabolic Health
Research field(s)
Helmholtz Diabetes Center
PSP Element(s)
G-502210-001
Grants
Copyright
Erfassungsdatum
2020-01-10